The influence of hormone replacement therapy on the salivary flow of post-menopausal women

Lago, Marília Leal Ferreira; Oliveira, Ana Emília Figueiredo de; Lopes, Fernanda Ferreira; Ferreira, Elza Bernardes; Rodrigues, Vandílson Pinheiro; Brito, Luciane Maria Oliveira

doi:10.3109/09513590.2014.959918

Cited by 15 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average of rest salivary flow found in this study was higher than the value found by Niklander [17] and Villa [20], what makes evident there is no functional changes on salivary glandules. When the average of stimulated salivary flow was observed, the results are according to those obtained by Falcão [21] and Lago [22]. This situation allows us to infer that drugs used on hormone therapy act on salivary glandules, decreasing their production when they suffer stimulation.…”

Section: Discussionsupporting

confidence: 67%

Cancer treatment through hormone therapy and its relationship with Xerostomia and Hyposalivation

Medeiros¹,

Fernandes²,

Pompeo³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: the emergence of new drugs for cancer treatment has reflected on increasing patient survival. However, these drugs bring side effects, such as dry mouth sensation and hyposalivation. This study aimed to evaluating the relationship between patients with cancer and xerostomia and hyposalivation. Method : cross-sectional study with 114 patients diagnosed with cancer treated with anastrozole and / or bicalutamide. Age, type of neoplasia, gender, xerostomia, and type of medicine were obtained through questionnaire. Resting and stimulated salivary flow were collected by the researcher. After collection, using a 10 mL disposable syringe, salivary flow was quantified in millimeters and divided into 6 (collection period). A Descriptive statistical analysis, Chi-square test and T-test were carried out through Statistical Package for Social Science® (SSPS) version 21, considering p<0.05. Results : results showed that 67 (55.8%) patients who use hormone therapy presented hyposalivation and 73 (64. 0%) patients presented xerostomia. Conclusion : According to the results from this study, there is statistically significant association between stimulated hyposalivation and hormone therapy usage (p = 0.015). Statistically significant association was also observed among hyposalivation and xerostomia and hormone therapy usage (p=0.049 and p = 0.001).

show abstract

Section: Discussionsupporting

confidence: 67%

Cancer treatment through hormone therapy and its relationship with Xerostomia and Hyposalivation

Medeiros¹,

Fernandes²,

Pompeo³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The means of stimulated salivary ow volume are similar to the values obtained by Rahnama et al [17] (0.812 ± 0.095 mL/min). Lago et al [18] observed that hormone therapy increases salivary ow in 0.52 mL/min, showing an in uence of hormone therapy drugs used by postmenopausal women, especially the ones under estroprogestative therapy. This study did not aim to assess whether women were pre-or postmenopausal, but it allows inferring that these drugs work on the salivary glands and affect salivary ow.…”

Section: Discussionmentioning

confidence: 99%

Cancer treatment with hormone therapy and its relationship with xerostomia and hyposalivation

Medeiros

Fernandes

Pompeo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The appearance of new drugs for cancer treatment has increased patient survival but it has also brought adverse effects, such as the sensation of dry mouth and hyposalivation. Objective: To assess the relationship of using hormone therapy in breast and prostate cancer patients and the occurrence of xerostomia and hyposalivation. Method: Cross-sectional study with 114 patients diagnosed with cancer and treated with hormone therapy (anastrozole or bicalutamide). Age, type of neoplasia, sex, presence of xerostomia (yes or no), and type of medication were obtained with a questionnaire. The researcher collected resting and stimulated salivary flows in the morning. The descriptive statistic analysis, chi-square test (p<0.005), and t-test (<0.005) were performed using the Statistical Package for Social Science™ (SSPS), version 21, for different variables of hyposalivation and hormone therapy. Results: The results showed that 67 (55.8%) patients using hormone therapy drugs presented hyposalivation and 73 (64%) patients presented xerostomia. Conclusion: According to the results of this study, there is a positive association between stimulated hyposalivation and the use of hormone therapy drugs (p = 0.015). There was also a positive association between hyposalivation and xerostomia and the use of hormone therapy drugs (p = 0.049 and p = 0.001).

show abstract

“…A clinical study demonstrated that therapy with estrogen hormone increased saliva production (16). Also, ovariectomized rats treated with estradiol returned the levels of muscarinic receptors to normal, indicating a protective role played by estrogen in saliva formation (17).…”

Section: Discussionmentioning

confidence: 99%

Calcium and Phosphorus Levels in Saliva are Influenced by Genetic Polymorphisms in Estrogen Receptor Alpha and Microrna17

et al. 2020

View full text Add to dashboard Cite

Homeostasis between salivary calcium and phosphorus is important for maintaining oral health. The aim of this study was to evaluate if polymorphisms in ESR1 (Estrogen Receptor Alpha), ESR2 (Estrogen Receptor Beta) and miRNA17 (microRNA17) are associated with calcium and phosphorus levels in saliva. Saliva from 276 12-year-old children were collected by masticatory stimulation and calcium and phosphorus levels were determined by Mass Spectrometry. Genomic DNA was extracted from remaining saliva and genetic polymorphisms in ESR1 (rs12154178, rs1884051, rs9340799 and rs2234693), in ESR2 (rs4986938 and rs1256049) and in miRNA17 (rs4284505) were genotyped using TaqMan chemistry and a real-time PCR equipment. Statistical differences in genotype and allele distributions between ‘low’ and ‘high’ calcium and phosphorus levels were determined using chi-square or Fisher´s exact tests. The analysis was also adjusted by sex (alpha of 5%). ESR1 rs9340799 had the less common genotype associated with higher calcium levels (p=0.03). The less common allele of ESR1 rs1884051 was associated with lower phosphorus levels (p=0.005) and there was an excess of heterozygotes for miRNA17 rs4284505 among individuals with lower calcium levels (p=0.002), both adjusted by sex. This study provides evidence that genetic polymorphisms in ESR1 and miRNA17 are involved in determining salivary calcium and phosphorus levels.

show abstract

The influence of hormone replacement therapy on the salivary flow of post-menopausal women

Cited by 15 publications

References 21 publications

Cancer treatment through hormone therapy and its relationship with Xerostomia and Hyposalivation

Cancer treatment through hormone therapy and its relationship with Xerostomia and Hyposalivation

Cancer treatment with hormone therapy and its relationship with xerostomia and hyposalivation

Calcium and Phosphorus Levels in Saliva are Influenced by Genetic Polymorphisms in Estrogen Receptor Alpha and Microrna17

Contact Info

Product

Resources

About